Evommune, Inc. (EVMN) Financials

EVMN Assets vs Liabilities
DateAssetsLiabilities
June 30, 2026 301.9 million 24.4 million
March 31, 2026 322.5 million 17.9 million
Dec. 31, 2025 224.9 million 19.4 million
Sept. 30, 2025 84.5 million 267.7 million

EVMN Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
June 30, 2026 -20.5 million 4.6 million
March 31, 2026 -27.6 million 3.5 million
Dec. 31, 2025 -16.8 million 4.2 million
Sept. 30, 2025 -9.8 million 560000

EVMN Net Income

No data available :(

EVMN Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
June 30, 2026 200.8 million - 8.1 million
March 31, 2026 211.5 million - 7.3 million
Dec. 31, 2025 149.2 million - 1.5 million
Sept. 30, 2025 76.1 million 257.0 million 261000

EVMN Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
June 30, 2026 36.1 million
March 31, 2026 33.7 million
Dec. 31, 2025 31.5 million
Sept. 30, 2025 31.5 million

EVMN Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
June 30, 2026 183000 26.4 million 8.5 million -
March 31, 2026 83000 17.3 million 6.3 million -
Dec. 31, 2025 104000 20.4 million 9.3 million 2.1 million
Sept. 30, 2025 131000 19.6 million 3.7 million -

EVMN Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
June 30, 2026 - -
March 31, 2026 - 349000
Dec. 31, 2025 - 326000
Sept. 30, 2025 10.0 million 311000

EVMN

Price: $14.65

52 week price:
10.47
33.20

Earnings Per Share: -11.75 USD

Exchange: NYQ

Sector: Healthcare

Industry: Biotechnology

Market Capitalization: 512.4 million

Links: